11 completed, 3 withdrawn, 2 recruiting, 2 unknown. 19 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 19 | Completed 11, Withdrawn 3, Recruiting 2, Unknown 2, Terminated 1 |
| Phase 1 | 4 | Completed 2, Withdrawn 2 |
Follow Papulopustular Rosacea: new trials by email Literature Review of Papulopustular Rosacea trials Research Report on Papulopustular Rosacea
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR) LOU064, Placebo - Papulopustular Rosacea | Phase 2 | Recruiting | Novartis Pharmaceuticals | 100 | 2026-07-30 | 2026-10-15 |
| Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea Clascoterone Cream 1% - Papular-pustular Rosacea, Papulopustular Rosacea (PPR) | Phase 2 | Recruiting | Narrows Institute for Biomedical Research | 20 | 2025-03-14 | 2025-05-06 |
| Deucravacitinib Rosacea Deucravacitinib, Placebo - Papulopustular Rosacea | Phase 2 | Withdrawn | Icahn School of Medicine at Mount Sinai | 2024-11-01 | 2025-01-24 | |
| Study to Evaluate the Safety of ATR-04 ATR-04, Placebo - Epidermal Growth Factor, Papulopustular Rosacea | Phase 1 / Phase 2 | Withdrawn | Azitra Inc. | 2024-01-01 | 2025-10-03 | |
| PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea PF-07038124, Placebo Ointment - Seborrheic Dermatitis, Papulopustular Rosacea | Phase 2 | Terminated | Icahn School of Medicine at Mount Sinai | 32 | 2023-07-19 | 2026-08-14 |
| Study of TP-04 in Participants With Papulopustular Rosacea Lotilaner Gel, 2.0%, Vehicle control gel - Papulopustular Rosacea | Phase 2 | Completed | Tarsus Pharmaceuticals, Inc. | 37 | 2023-03-01 | 2023-11-24 |
| Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea Rifaximin, Placebo - Papulopustular Rosacea | Phase 2 | Completed | Alfasigma S.p.A. | 216 | 2021-10-05 | 2024-04-24 |
| A Safety and Efficacy Study to Evaluate Rosacea AIV001, Vehicle - Papulopustular Rosacea | Phase 1 / Phase 2 | Withdrawn | AiViva BioPharma, Inc. | 2021-07-01 | 2024-12-17 | |
| Topical Minocycline Gel for Inflammatory Lesions of Papulopustular Rosacea minocycline topical gel, topical gel vehicle - Papulopustular Rosacea | Phase 2 | Unknown | BioPharmX, Inc. | 207 | 2018-09-18 | 2019-07-10 |
| Safety and Efficacy of Rifaximin in Patients With Papulopustular Rosacea and Positive Lactulose Breath Test Rifaximin delayed release 400 mg tablet, Placebo - Papulopustular Rosacea | Phase 2 | Unknown | Alfasigma S.p.A. | 236 | 2018-06-22 | 2019-03-11 |
| Study to Evaluate the Safety and Efficacy of Topical Minocycline Gel in Patients With Papulopustular Rosacea 1% Topical Minocycline Gel, 3% Topical Minocycline Gel, Topical Vehicle Gel - Rosacea, Papulopustular Rosacea | Phase 2 | Completed | Hovione Scientia Limited | 270 | 2017-10-30 | 2019-11-08 |
| Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea Secukinumab - Papulopustular Rosacea | Phase 1 / Phase 2 | Completed | Anne Chang | 24 | 2017-06-21 | 2020-02-05 |
| Safety and Efficacy Study of a Topical Minocycline Foam in Patients With Papulopustular Rosacea FMX-103 1.5%, FMX-103 3%, Vehicle foam (0%) - Rosacea, Papulopustular Rosacea | Phase 2 | Completed | Vyne Therapeutics Inc. | 233 | 2015-09-01 | 2017-02-15 |
| An Analysis of the Effect of Topical Cromolyn Sodium on Rosacea-associated Erythema Cromolyn Sodium, Normal Saline - Papulopustular Rosacea | Phase 1 / Phase 2 | Completed | University of California, San Diego | 10 | 2013-08-01 | 2019-08-07 |
| A Twelve Week Safety and Efficacy Study in Rosacea omiganan, placebo - Papulopustular Rosacea | Phase 2 | Completed | Maruho Co., Ltd. | 240 | 2013-03-01 | 2015-05-20 |
| Study to Evaluate the Efficacy and Safety of PAC-14028 Cream in Rosacea Patients PAC-14028 cream 1%, Vehicle, Rozex gel 0.75% - Erythematotelangiectatic Rosacea, Papulopustular Rosacea | Phase 2 | Completed | Amorepacific Corporation | 80 | 2013-02-01 | 2014-02-03 |
| Open Label Pilot Study of Apremilast in Treatment of Rosacea Apremilast - Erythematotelangiectatic Rosacea, Papulopustular Rosacea | Phase 2 | Completed | Julian M. Mackay-Wiggan | 10 | 2010-06-01 | 2016-12-13 |
| Safety and Efficacy of Azelaic Acid Foam, 15% in Papulopustular Rosacea Azelaic acid foam 15%, Vehicle foam - Papulopustular Rosacea | Phase 2 | Completed | LEO Pharma | 401 | 2009-12-01 | 2020-03-31 |
| Exploration of Safety and Efficacy of AzA 15% Foam Twice a Day in Rosacea Azelaic acid, Vehicle foam - Papulopustular Rosacea | Phase 2 | Completed | LEO Pharma | 83 | 2008-01-01 | 2020-04-07 |
Rosacea (19) · Dermatitis, Seborrheic (1) · Primary hyperoxaluria type 2 (1) · Skin Diseases (1) · Telangiectasis (1) · cyclopia sequence (1)
Skin and Connective Tissue Diseases (19) · Skin Diseases (18) · Cardiovascular Diseases (1) · Dermatitis (1) · Sebaceous Gland Diseases (1) · Skin Diseases, Eczematous (1) · Skin Diseases, Papulosquamous (1) · Vascular Diseases (1)
Clascoterone (1) · Cromolyn Sodium (1) · Gels (1) · N-(1-(3,5-difluoro-4-methanesulfonylaminophenyl)ethyl)-3-(2-propyl-6-trifluoromethylpyridine-3-yl)acrylamide (1) · Omiganan (1) · Rifaximin (1) · Saline Solution (1) · Sodium Chloride (1) · Tablets (1) · apremilast (1) · azelaic acid (1) · deucravacitinib (1) · guselkumab (1) · remibrutinib (1) · secukinumab (1)
Alfasigma S.p.A. (2) · Icahn School of Medicine at Mount Sinai (2) · LEO Pharma (2) · AiViva BioPharma, Inc. (1) · Amorepacific Corporation (1) · Anne Chang (1) · Azitra Inc. (1) · BioPharmX, Inc. (1) · Hovione Scientia Limited (1) · Julian M. Mackay-Wiggan (1) · Maruho Co., Ltd. (1) · Narrows Institute for Biomedical Research (1) · Novartis Pharmaceuticals (1) · Tarsus Pharmaceuticals, Inc. (1) · University of California, San Diego (1)
United States (14) · Canada (2) · Germany (2) · South Korea (2) · Bulgaria (1) · China (1) · Italy (1) · Singapore (1) · Spain (1)
AnnaMarie Daniels (1) · Anne Chang, MD (1) · Benjamin Ungar (1) · Benjamin Ungar, MD (1) · BeomJoon Kim, Professor (1) · Jared Jagdeo, MD MS (1) · Jose Trevejo, MD, PhD (1) · Julian Mackay-Wiggan, MD, MS (1) · Mitchell Goldman, MD (1) · Sunil S Dhawan, MD (1) · Ulrich Mrowietz, MD (1)
2017 (1), 2025 (1)